EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSOKIG00005019614
Gene Symbol: LOC109866710
2 Cross references
7 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSOKIG00005010494
Gene Symbol: MAP3K5
1 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSOKIG00005042568
Gene Symbol: MAP3K8
1 Cross references
194 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSOKIG00005040048
Gene Symbol: MAP3K8
3 Cross references
194 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSOKIG00005015417
Gene Symbol: MAP3K9
3 Cross references
195 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSOKIG00005005188
Gene Symbol: LOC109907835
3 Cross references
202 Possible Orthologues:

Monoglyceride Lipase-Like

Ensembl ID : ENSOKIG00005049360
Gene Symbol: LOC109869337
3 Cross references
202 Possible Orthologues:

Muscarinic Acetylcholine Receptor M2

Ensembl ID : ENSOKIG00005004159
Gene Symbol: LOC109887850
3 Cross references
189 Possible Orthologues:

Natriuretic Peptide Receptor 1a

Ensembl ID : ENSOKIG00005030936
Gene Symbol: NPR1A
1 Cross references
187 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSOKIG00005015026
Gene Symbol: NPR2
1 Cross references
185 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1

Ensembl ID : ENSOKIG00005049913
Gene Symbol: LOC109895752
3 Cross references
194 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 2-Like

Ensembl ID : ENSOKIG00005002709
Gene Symbol: LOC109885731
3 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).